HALO Stock Forecast: Halozyme Therapeutics, Inc. Price Predictions for 2026-2027
The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. hold a median 12-month price target of $125 — +36.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 96 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Halozyme Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
HALO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on HALO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +36.8% from it.
Of the 20 most recent actions, 14 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $130 |
| 11 Nov 2026 | Morgan Stanley | Downgrade | Equal-Weight | $105 → $109 |
| 7 Nov 2026 | Leerink Partners | Downgrade | Market Perform | — |
| 6 Nov 2026 | Citizens | Maintains | Market Outperform | $93 → $149 |
| 6 Nov 2026 | Evercore ISI Group | Maintains | Outperform | $123 → $125 |
| 6 Nov 2026 | Leerink Partners | Downgrade | Market Perform | $110 → $117 |
| 6 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $95 → $110 |
| 3 Nov 2026 | JP Morgan | Maintains | Neutral | $78 → $79 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $105 → $130 |
| 8 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $115 → $130 |
| 8 Oct 2026 | JP Morgan | Maintains | Neutral | $70 → $78 |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $115 |
| 8 Aug 2026 | Leerink Partners | Upgrade | Outperform | — |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | $92 → $93 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $95 → $115 |
| 7 Aug 2026 | Leerink Partners | Upgrade | Outperform | $83 → $110 |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | $96 → $105 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $75 → $95 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | $96 → $93 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for HALO.
This page is one stock. Monday covers all of them.
HALO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
HALO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Halozyme Therapeutics, Inc. returned +32.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
HALO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 23.1×
- Price / sales
- 5.9×
- Price / book
- 75.8×
- EV / EBITDA
- 11.2×
Cheaper than 38% of US stocks
Cheaper than 18% of US stocks
Cheaper than 1% of US stocks
Cheaper than 50% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 41.0%
- Gross margin
- 83.5%
- Operating margin
- 56.7%
- Net margin
- 26.9%
Higher than 72% of US stocks
Higher than 93% of US stocks
Higher than 98% of US stocks
Higher than 86% of US stocks
- Return on equity
- 216.4%
- Return on assets
- 22.4%
- Dividend yield
- —
Higher than 98% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Halozyme Therapeutics, Inc. has a market value of $10.6B and an enterprise value of $12.8B.
Revenue in the twelve months to 30 June 2026: $1.7B. The latest quarter grew 47.7% year on year.
Net income over the same four quarters: $413.6M, a 24.9% net margin.
Diluted earnings per share, trailing twelve months: $3.35.
Free cash flow in the twelve months to 30 June 2026: $518.5M.
Trailing P/E: 23.1×; forward P/E: 8.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Halozyme Therapeutics, Inc. employs 423 people — $3.9M of revenue per employee.
Data provided by Twelve Data
HALO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at HALO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Halozyme Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about HALO
What is the HALO stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. have a median 12-month price target of $125, with estimates ranging from $81 to $149. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is HALO stock a buy right now?
Of the 9 analysts covering Halozyme Therapeutics, Inc., 5 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Halozyme Therapeutics, Inc. 96 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank HALO?
As at 21 Nov 2026, Halozyme Therapeutics, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
Will HALO stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +36.8% from the last close, and Ticker Nerd's factor model ranks Halozyme Therapeutics, Inc. 96 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the HALO stock forecast for 2030?
No analyst covering Halozyme Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HALO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $81 to $149 over the next 12 months.
How has HALO stock performed over the past year?
Halozyme Therapeutics, Inc. returned +32.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Halozyme Therapeutics, Inc. do?
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. · 423 employees · United States · https://halozyme.com